JANX
Janux Therapeutics Inc
16.90$
-0.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -1.7% | +81.1% | +0.4% | +0.5% | +52.7% | -1.0% | -1.8% | -0.7% | -1.7% | +2.1% | -2.0% | |
| – | -1.7% | +88.6% | +0.5% | +0.7% | +55.1% | -1.0% | -1.7% | -0.7% | -2.2% | +2.7% | -1.9% | |
| – | +12.0% | +1,008.1% | -93.1% | +82.5% | +1,509.5% | -82.9% | -28.9% | -7.7% | +8.2% | -1.0% | -46.4% | |
| – | -1.6% | +89.5% | -0.8% | +1.8% | +55.8% | -1.1% | -1.8% | -0.7% | -2.3% | -1.1% | +1.5% | |
| – | +29.4% | +100.2% | +173.7% | -63.1% | +20.8% | +3.8% | +1.9% | +11.0% | +1.8% | +560.6% | -85.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -4.9% | -7.9% | +1.5% | +15.4% | -0.5% | -1.1% | +8.9% | +15.6% | +5.2% | +71.0% | -8.1% | |
| – | -9.9% | -18.6% | +8.8% | +48.7% | +1.7% | +0.2% | +22.2% | +30.2% | -10.2% | +135.7% | +2.1% | |
| – | +3.8% | +3.7% | +3.6% | +3.6% | +3.6% | +3.5% | +3.4% | +21.7% | +5.0% | +3.3% | +3.2% | |
| – | -3.2% | -7.0% | -44.4% | +96.5% | +63.5% | -41.6% | +47.9% | -2.4% | +46.4% | -32.1% | -10.6% | |
| – | -1.3% | +90.4% | +0.3% | -0.2% | +55.9% | -1.0% | -2.2% | -1.4% | -2.0% | -1.6% | -1.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.1% | +5.1% | +11.0% | +0.3% | +4.0% | +8.7% | +0.2% | +0.2% | -0.1% | +1.1% | +0.4% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.